Poorer survival for patients with inflammatory arthritis treated with immune checkpoint inhibitors for melanoma
Patients with inflammatory arthritis have poorer OS and PFS/RFS following ICI therapy for melanoma, partly attributable to baseline immunosuppressive treatment. These findings underscore the need for enhanced multidisciplinary management to optimize outcomes and address the survival gap in this population.
Authors
- Hanne Lindegaard (ORCID: https://orcid.org/0000-0002-5675-3859)
- Søren Andreas Just (ORCID: https://orcid.org/0000-0002-3946-5919)
- Christina H. Bruvik Ruhlmann (ORCID: https://orcid.org/0000-0002-3728-273X)
- Susanne K. Kjær (ORCID: https://orcid.org/0000-0002-8347-1398)
- Sören Möller (ORCID: https://orcid.org/0000-0003-0858-4269)
- Lars Bastholt (ORCID: https://orcid.org/0000-0001-5478-9826)
- Helene Broch Tenstad (ORCID: https://orcid.org/0000-0002-3403-9865)
Institutions
- University of Southern Denmark (DK)
- Odense University Hospital (DK)
- Region of Southern Denmark (DK)
- Svendborg Sygehus (DK)
Publication Details
- Journal
- Journal of Autoimmunity
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1016/j.jaut.2025.103400
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09